I'm LongbridgeAI, I can summarize articles.Pharmaron Beijing Co., Ltd. has raised approximately HK$1.32 billion through the placement of 58,440,762 new H shares at HK$22.82 per share. The funds will be used for expanding project development, increasing laboratory services and drug manufacturing capabilities, and for debt repayment. Following this transaction, the proportion of H shares increased from 16.62% to 19.28%, slightly diluting existing holdings. The company's market cap is HK$56.88 billion, with a current analyst rating of Hold and a price target of HK$24.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) is now available.
Pharmaron Beijing Co., Ltd. has completed a placing of 58,440,762 new H shares under its general issuance mandate, raising net proceeds of approximately HK$1.32 billion through placements to at least six independent investors at HK$22.82 per share. The funds will primarily be used to expand project development and increase capabilities and production capacity in laboratory services and drug process development and manufacturing facilities, with smaller portions allocated to debt repayment and working capital. Following the transaction, total issued share capital has risen to 1,829,372,987 shares, increasing the proportion of H shares from 16.62% to 19.28% and slightly diluting existing A-share and H-share holdings, thereby broadening the company’s international investor base and optimizing its capital structure.
The most recent analyst rating on (HK:3759) stock is a Hold with a HK$24.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-based pharmaceutical research and development services provider listed in Hong Kong, offering laboratory services, drug process development and manufacturing capabilities. The company focuses on expanding its R&D and production capacity to support global biopharmaceutical clients and strengthen its position in the contract research and manufacturing organization segment.
Average Trading Volume: 5,847,219
Technical Sentiment Signal: Buy
Current Market Cap: HK$56.88B
Find detailed analytics on 3759 stock on TipRanks’ Stock Analysis page.